New Blood Test Could Revolutionise Alzheimer’s Diagnosis
Sysmex and Japanese drugmaker Eisai have struck gold with a breakthrough blood test for Alzheimer’s. The kit, given the green light by regulators on December 19, can spot amyloid beta buildup in the brain using just a small blood sample. This is a game-changer for tens of millions suffering worldwide.
Faster, Cheaper, Less Invasive
Current Alzheimer’s diagnosis involves costly, invasive brain scans or spinal taps. Sysmex says their test slashes the physical, emotional, and financial toll on patients. “Unlike conventional methods, our blood test quickly identifies amyloid beta accumulation,” said the company. They’re racing to bring it to market ASAP.
A Breakthrough Backed by Big Pharma
The Alzheimer’s Association calls the test “simple, inexpensive, non-invasive,” and believes such tools could revolutionise dementia diagnosis. Meanwhile, Eisai and US partner Biogen are pushing for full approval of their experimental Alzheimer’s drug, lecanemab, across the US, Europe, and Japan next year.
Recent data showed lecanemab slows cognitive decline by 27% over 18 months. Though some side effects like brain bleeds and swelling were noticed, the drug is hailed as a “real treatment option” for degenerative brain disease.
Why This Matters
- Alzheimer’s is caused by protein clumps, tau and amyloid beta, that kill brain cells.
- Early detection is key to slowing the disease.
- With a simple blood test, doctors can diagnose and treat earlier than ever before.
This new blood test could change the Alzheimer’s landscape forever. Watch this space for a possible revolution in dementia care.
